title: [Reduction in oxaliplatin-related neurotoxicity by the administration of Keishikajutsubuto(TJ-18)and powdered processed aconite root].
abstract: Oxaliplatin (L-OHP)is an important chemotherapeutic drug for the treatment of colorectal cancer. Peripheral neuropathy was observed in 90% of patients who received L-OHP.Neuropathy often results in the discontinuation of treatment or a decrease the quality of life(QOL). The most effective method for reducing neuropathy is the discontinuation of L-OHP. To reduce neuropathy, we administered Keishikajutsubutou(TJ-18)with powdered processed aconite root(TJ-3023), and we report the effect of these compounds. The subjects comprised 11 patients with metastatic colorectal cancer. L-OHP(85mg/m2)was administered as part of the FOLFOX6(10 patients)or FOLFOX7(1 patient)regimen. All patients had experienced neuropathy. We administered TJ-18(7.5 g)and T-3023(1 g). After 2 weeks, the TJ-3023 dose was increased to 2 g for nonresponders. The response was evaluated according to the Neurotoxicity Criteria of DEBIOPHARM. Reduction in neuropathy was observed in 5 cases(45.5% ). Among 6 patients whose feet and hands felt warm, reduction in neuropathy was observed in 5(83.3% ).
authors.affiliation: Dept. of Surgery, Nippon Medical School.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Hayato
authors.initials: H
authors.lastname: Kan
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Michihiro
authors.initials: M
authors.lastname: Koizumi
authors.forename: Junpei
authors.initials: J
authors.lastname: Sasaki
authors.forename: Aya
authors.initials: A
authors.lastname: Tani
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Yokoi
authors.forename: Eiji
authors.initials: E
authors.lastname: Uchida
mesh_terms: D031841:Aconitum / Q000737:chemistry*; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D008517:Phytotherapy; D018517:Plant Roots / Q000737:chemistry; D011208:Powders
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D009944:Organoplatinum Compounds; D011208:Powders; C477943:keishi-ka-jutsubu-to; D000077150:Oxaliplatin